Breaking News
Get 40% Off 0
Join +750K new investors every month who copy stock picks from billionaire's portfolios Sign Up Free
Close

Regeneron Pharmaceuticals Inc (REGN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Regeneron Pharma's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1,036.52 +9.97    +0.97%
- Closed. Currency in USD ( Disclaimer )
After Hours
1,044.78
+8.26
+0.80%
- Real-time Data
Type:  Equity
Market:  United States
  • Volume: 353,213
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 1,018.08 - 1,042.66
Regeneron Pharma 1,036.52 +9.97 +0.97%

NASDAQ:REGN Financials

 
A brief overview of the NASDAQ:REGN financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Regeneron over time.

Regeneron Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 3,145 million compared to USD 3,162.1 million a year ago. Net income was USD 722 million compared to USD 817.8 million a year ago. Basic earnings per share from continuing operations was USD 6.7 compared to USD 7.64 a year ago. Diluted earnings per share from continuing operations was USD 6.27 compared to USD 7.17 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

REGN Income Statement

Gross margin TTM 51.31%
Operating margin TTM 30.45%
Net Profit margin TTM 29.45%
Return on Investment TTM 12.85%
 Total Revenue  Net Income
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Revenue 3145 3434.3 3362.7 3158.1
Gross Profit 1467 1740.1 1851 1667.9
Operating Income 758.5 1002.9 1211 1016.5
Net Income 722 1159.6 1007.8 968.4

REGN Balance Sheet

Quick Ratio MRQ 3.98
Current Ratio MRQ 5.27
LT Debt to Equity MRQ 7.35%
Total Debt to Equity MRQ 10.02%
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Assets 34369.6 33080.2 32163.3 30657.5
Total Liabilities 7378.5 7107.1 7258.9 6639.6
Total Equity 26991.1 25973.1 24904.4 24017.9

REGN Cash Flow Statement

Cash Flow/Share TTM 44.1
Revenue/Share TTM 121.9
Operating Cash Flow  0.00%
 Cash  Net Change in Cash
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 1089.7 1114.3 1022.4
Cash From Investing Activities -66.2 -496.3 -2386.9
Cash From Financing Activities -446.1 -407.3 -614.2
Net Change in Cash 577.6 210.5 -1979.1
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

REGN Comments

Write your thoughts about Regeneron Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
양 한
양 한 Aug 24, 2023 10:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Scd411 is imminent
Avi Kalo
Avi Kalo Feb 03, 2023 9:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
REGN Earnings are wrong !!! it was 3.41B not M
borat smagadijev
borat smagadijev Jun 09, 2022 3:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Falling knife
Petet Larkar
Petet Larkar Jun 09, 2022 3:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I want your ******
Carmen Esparza
Carmen Esparza Jan 10, 2022 2:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Eliav Biton
Eliav Biton Nov 17, 2021 1:30AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
best opportunity in this market
Financial Advisors
Financial Advisors Nov 04, 2021 6:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
only take long positions .
David Lousada
David Lousada Nov 04, 2021 6:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
huge earnings beat!
Richard Senato
Richard Senato Sep 13, 2021 11:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Whats happening
Marut Patphol
Marut Patphol Sep 13, 2021 11:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Fall
ken ken
ken ken Sep 13, 2021 11:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Most of sales in this quarters are from COVID, and competion announced results
York Regent
York Regent Aug 05, 2021 9:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Acquiring Inovio will propel REGN closer to COVID 19 vaccine and clear path to 1K a share.
York Regent
York Regent Aug 05, 2021 9:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This should boost Inovio. Time to pile up.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email